{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:50:37Z","timestamp":1793746237980,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1053\/j.gastro.2007.11.036","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T21:20:26Z","timestamp":1196889626000},"page":"405-415","source":"Crossref","is-referenced-by-count":187,"title":["Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach"],"prefix":"10.1053","volume":"134","author":[{"given":"Jean\u2013Michel","family":"Pawlotsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Hatzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Jake","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas D.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2007.11.036_bib1","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection\u2014natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(04)00162-7","article-title":"Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection","volume":"64","author":"Zoulim","year":"2004","journal-title":"Antiviral Res"},{"key":"10.1053\/j.gastro.2007.11.036_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","article-title":"A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B","volume":"323","author":"Perrillo","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/gast.2001.25524","article-title":"Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"121","author":"Manesis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1053\/j.gastro.2007.11.036_bib12","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib14","first-page":"222A","article-title":"Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) versus lamivudine","volume":"44","author":"Lai","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib16","first-page":"193A","article-title":"Entecavir is superior to lamivudine for the treatment of HBeAg-positive chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients","volume":"40","author":"Chang","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib18","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.11.036_bib21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","article-title":"Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men","volume":"97","author":"Yu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2007.11.036_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature","volume":"37","author":"Mommeja-Marin","year":"2003","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2007.11.036_bib26","first-page":"229A","article-title":"Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib27","first-page":"230A","article-title":"Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients","volume":"44","author":"Di Bisceglie","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy","volume":"34","author":"Yuen","year":"2001","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib29","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/j.1572-0241.2003.07643.x","article-title":"A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine","volume":"98","author":"Ide","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2007.11.036_bib30","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib31","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","author":"Laras","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib34","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2005.11.020","article-title":"Assessment of treatment efficacy in HBV infection and disease","volume":"44","author":"Zoulim","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1572-0241.2005.41530.x","article-title":"Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection","volume":"100","author":"Yuen","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2007.11.036_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.20353","article-title":"Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2004.12.015","article-title":"New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA","volume":"42","author":"Zoulim","year":"2005","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib38","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1182\/blood-2004-09-3402","article-title":"Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy","volume":"105","author":"Hui","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.gastro.2007.11.036_bib39","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1099\/0022-1317-83-6-1267","article-title":"Genetic variability in hepatitis B viruses","volume":"83","author":"Kidd-Ljunggren","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib40","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1099\/0022-1317-83-8-2059","article-title":"Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America","volume":"83","author":"Arauz-Ruiz","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2005.03.018","volume":"43","author":"Chu","year":"2005","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib42","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/jhep.2001.27221","article-title":"Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan","volume":"34","author":"Orito","year":"2001","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0168-8278(00)80279-2","article-title":"Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity","volume":"33","author":"Grandjacques","year":"2000","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2893.2002.00304.x","article-title":"Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants","volume":"9","author":"Funk","year":"2002","journal-title":"J Viral Hepat"},{"key":"10.1053\/j.gastro.2007.11.036_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/509894","article-title":"Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F","volume":"195","author":"Livingston","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2007.11.036_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2007.11.036_bib47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with peginterferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2007.11.036_bib48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/jhep.2000.19619","article-title":"Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B","volume":"32","author":"Nafa","year":"2000","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcv.2005.05.008","article-title":"Evaluation of the MagNA Pure LC used with the Trugene HBV Genotyping Kit","volume":"34","author":"Gintowt","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2004.01.006","article-title":"Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments","volume":"40","author":"Hong","year":"2004","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib51","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1128\/JCM.44.3.1094-1097.2006","article-title":"Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir","volume":"44","author":"Hussain","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.gastro.2007.11.036_bib52","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/135965350501000306","article-title":"Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization","volume":"10","author":"Kim","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2007.11.036_bib53","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/JCM.02477-05","article-title":"Detection of rtN236T and rtA181V\/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2)","volume":"44","author":"Osiowy","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib54","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(07)61653-5","article-title":"Complex dynamics of hepatitis B virus resistance to adefovir dipivoxil","volume":"46","author":"Pallier","year":"2007","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1179\/joc.2005.17.5.514","article-title":"Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B","volume":"17","author":"Sertoz","year":"2005","journal-title":"J Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib56","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.80.2.643-653.2006","article-title":"Dynamics of hepatitis B virus resistance to lamivudine","volume":"80","author":"Pallier","year":"2006","journal-title":"J Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1423-0410.2001.00003.x","article-title":"An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques","volume":"80","author":"Saldanha","year":"2001","journal-title":"Vox Sang"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib58","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8278(03)00136-3","article-title":"Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics","volume":"39","author":"Pawlotsky","year":"2003","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib59","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/gast.2002.33428","article-title":"Molecular diagnosis of viral hepatitis","volume":"122","author":"Pawlotsky","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib60","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1128\/JCM.43.7.3504-3507.2005","article-title":"Evaluation of the Cobas TaqMan 48 real-time PCR system for quantitation of hepatitis B virus DNA","volume":"43","author":"Gordillo","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.gastro.2007.11.036_bib61","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcv.2006.01.003","article-title":"Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the Cobas AmpliPrep\/Cobas TaqMan system","volume":"35","author":"Hochberger","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib62","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1128\/JCM.00732-06","article-title":"Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study","volume":"44","author":"Laperche","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.gastro.2007.11.036_bib63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jviromet.2006.02.004","article-title":"Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes","volume":"135","author":"Lole","year":"2006","journal-title":"J Virol Methods"},{"key":"10.1053\/j.gastro.2007.11.036_bib64","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/JCM.44.4.1390-1399.2006","article-title":"Evaluation of the Cobas AmpliPrep-total nucleic acid isolation-Cobas TaqMan hepatitis B virus (HBV) quantitative test and comparison to the Versant HBV DNA 3.0 assay","volume":"44","author":"Ronsin","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.gastro.2007.11.036_bib65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jmv.20481","article-title":"Comparison of the Cobas TaqMan HBV test with the COBAS Amplicor monitor test for measurement of hepatitis B virus DNA in serum","volume":"77","author":"Sum","year":"2005","journal-title":"J Med Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib66","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2004.02.009","article-title":"Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR","volume":"40","author":"Punia","year":"2004","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib67","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S1386-6532(05)80021-6","article-title":"The concept of hepatitis B virus mutant escape","volume":"34","author":"Pawlotsky","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1053\/j.gastro.2007.11.036_bib68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib69","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2006.08.013","article-title":"Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient","volume":"131","author":"Villet","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2007.11.036_bib70","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1128\/AAC.45.9.2495-2501.2001","article-title":"In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyluracil","volume":"45","author":"Chin","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/AAC.45.6.1705-1713.2001","article-title":"Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus","volume":"45","author":"Delaney","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib72","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib73","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hep.20388","article-title":"A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus","volume":"40","author":"Durantel","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib74","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/AAC.47.6.1936-1942.2003","article-title":"Generation of stable cell lines expressing lamivudine-resistant hepatitis B virus for antiviral-compound screening","volume":"47","author":"Walters","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2893.2000.00192.x","article-title":"Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.11.036_bib76","first-page":"252A","article-title":"Large variation in the replication efficiencies of HBV mutants: implications for phenotypic assays for antiviral drug resistance","volume":"44","author":"Shaw","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-147-1-200707030-00010","article-title":"The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and endpoints","volume":"147","author":"Lai","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7326\/0003-4819-147-1-200707030-00011","article-title":"When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?","volume":"147","author":"Degertekin","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.11.036_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib80","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.510290119","article-title":"Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance","volume":"29","author":"Pichoud","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib81","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistance in patients with chronic hepatitis B","volume":"9","author":"Locarnini","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2007.11.036_bib82","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib83","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an Adult Aids Clinical Trials Group Study","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2007.11.036_bib84","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00228-006-0162-7","article-title":"Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers","volume":"62","author":"Joerger","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2007.11.036_bib85","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/jhep.2000.18194","article-title":"The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B","volume":"32","author":"Richman","year":"2000","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2007.11.036_bib86","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2007.11.036_bib87","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2007.11.036_bib88","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/S0168-8278(06)80490-3","article-title":"High barrier to resistance results in no emergence of entecavir resistance in nucleoside-na\u00efve subjects during the first two years of therapy","volume":"44","author":"Colonno","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2007.11.036_bib89","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib90","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/AAC.00833-06","article-title":"Two-year entecavir resistance in lamivudine refractory HBV patients reveals different clinical outcomes depending on the resistance substitutions present","volume":"51","author":"Tenney","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2007.11.036_bib91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/135965359900400101","article-title":"Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation","volume":"4","author":"Cane","year":"1999","journal-title":"Antivir Ther"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508507021130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508507021130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T04:25:52Z","timestamp":1684124752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508507021130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0016508507021130"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2007.11.036","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}